FairJourney Bio opened an advanced cryo-electron microscopy (cryo-EM) structural biology facility in San Diego, expanding its U.S. footprint and integrating atomic-resolution structural biology directly into its antibody discovery platform. The site features a 300 kV cryo-EM infrastructure, including two ThermoFisher Titan Krios 5 systems. The company says the new facility houses native-state structure determination capabilities for antibody-target complexes and complements antibody discovery and biologic development services already offered across its U.S. and European operations. FairJourney also noted that cryo-EM services launched in January 2026. In practical drug discovery terms, the expansion is aimed at earlier structure-guided lead optimization—shifting cryo-EM from a late-stage confirmation tool toward a decision-shaping input during epitope mapping and candidate selection. For CRO/CDMO customers and antibody developers, the move strengthens access to high-end structural biology services in a major biotech hub, potentially shortening iteration cycles between discovery hypotheses and structural validation.